All posts tagged: Drug Trial

Abnormal Bone

Drug Trial Shows Reduced Abnormal Bone Formation in Those with Fibrodysplasia Ossificans Progressiva

A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva (FOP). Kathryn Dahir, MD, professor of Medicine in the Division of Endocrinology and Diabetes, served as the principal investigator at Vanderbilt University […]

Read more